APTA - Ticker AI Digest

Aptamer Group PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (APTA) 1
APTA 06:01
Aptamer Group PLC
New contract with Metir plc
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC (AIMAPTA) has signed a new contract with Metir PLC (AIM: MET) to develop Optimer® binders for rapid detection of *Cryptosporidium parvum* oocysts in Metirs next-generation Pathogen Detector platform. This collaboration builds on a previous agreement announced in June 2024, focusing on creating high-affinity binders for real-time water quality monitoring. The Optimer® technology offers high specificity, stability, and scalability, enabling faster contamination detection compared to traditional lab methods. The staged program aims to deliver proof-of-concept data within three months, advancing Metirs platform toward initial trials with UK water companies. This partnership strengthens both companies positions in innovative environmental and healthcare monitoring solutions, with Aptamers technology playing a key role in enhancing public health through water purity protection.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
APTA 06:01
Aptamer Group PLC
Therapeutic development agreement with Invizius
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc has signed a therapeutic development agreement with Invizius, a clinical-stage biotechnology company, to develop Optimer® binders targeting the complement system for treating inflammatory, fibrotic, and autoimmune diseases. The partnership aims to enhance Invizius H-Guard® therapy, making it safer and more precise by leveraging Aptamers synthetic oligonucleotide-based binders. These Optimers offer advantages such as enhanced specificity, biological stability, and reduced immunogenicity compared to protein-based therapeutics. The collaboration focuses on addressing diseases like IgA nephropathy, with the potential to tap into the $7.1 billion global market for complement-targeting therapies. Aptamer retains intellectual property rights for the developed binders, supporting future licensing and commercialization opportunities. The agreement aligns with Aptamers licensing-led growth model and reinforces its commitment to generating long-term shareholder value through royalty and licensing income. Invizius selected Aptamer for its expertise in delivering high-performance binders, highlighting the strategic fit and potential of aptamers as a future therapeutic modality.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
APTA 06:01
Aptamer Group PLC
Notification of dealings by a director/PDMR
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the <mark style="background-color:yellow">purchase</mark> of ordinary shares by directors and other PDMRs in the Company.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
APTA 06:01
Aptamer Group PLC
Biomarker Discovery Service Launch
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc (AIMAPTA) has launched a new **Biomarker Discovery Service**, leveraging its proprietary **Optimer® technology** and advanced proteomic analysis to rapidly identify and validate drug-development-ready biomarkers. This service targets the **US$62.4 billion global biomarker discovery market**, offering a fee-for-service model that accelerates biomarker identification from years to months. The platform simultaneously generates high-affinity binding molecules, enabling faster development of targeted therapies, diagnostics, and treatments.
The service addresses the critical need for biomarkers in precision medicine, particularly in areas with high unmet medical need. Early interest has been demonstrated, including successful internal application for Aptamer’s fibrotic liver delivery system. The launch supports Aptamer’s revenue diversification strategy, with minimal upfront investment and expected revenue enhancement in the current financial year.
CEO Dr. Arron Tolley highlighted the service’s potential to accelerate drug and diagnostic development, with two additional biomarker projects already underway. Aptamer’s Optimer® platform continues to expand its commercial impact, positioning the company as a leader in next-generation synthetic binders for the life sciences industry.
**Key Points**
Launch of Biomarker Discovery Service using Optimer® technology.
Targets US$62.4 billion global market with fee-for-service model.
Accelerates biomarker discovery from years to months.
Dual-output capabilityvalidated biomarkers + binding molecules.
Early interest and successful internal application demonstrated.
Expected revenue enhancement in the current financial year.
Supports Aptamer’s revenue diversification and growth strategy.
Litigation 0
No items for this category on selected date.
NewContract 2
APTA 06:01
Aptamer Group PLC
New contract with Metir plc
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC (AIMAPTA) has signed a new contract with Metir PLC (AIM: MET) to develop Optimer® binders for rapid detection of *Cryptosporidium parvum* oocysts in Metirs next-generation Pathogen Detector platform. This collaboration builds on a previous agreement announced in June 2024, focusing on creating high-affinity binders for real-time water quality monitoring. The Optimer® technology offers high specificity, stability, and scalability, enabling faster contamination detection compared to traditional lab methods. The staged program aims to deliver proof-of-concept data within three months, advancing Metirs platform toward initial trials with UK water companies. This partnership strengthens both companies positions in innovative environmental and healthcare monitoring solutions, with Aptamers technology playing a key role in enhancing public health through water purity protection.
APTA 06:01
Aptamer Group PLC
Contract extension with global pharma partner
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
APTA 14:45
Aptamer Group PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
APTA 06:01
Aptamer Group PLC
Update on licensing and development progress
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 9
APTA 06:01
Aptamer Group PLC
New contract with Metir plc
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC (AIMAPTA) has signed a new contract with Metir PLC (AIM: MET) to develop Optimer® binders for rapid detection of *Cryptosporidium parvum* oocysts in Metirs next-generation Pathogen Detector platform. This collaboration builds on a previous agreement announced in June 2024, focusing on creating high-affinity binders for real-time water quality monitoring. The Optimer® technology offers high specificity, stability, and scalability, enabling faster contamination detection compared to traditional lab methods. The staged program aims to deliver proof-of-concept data within three months, advancing Metirs platform toward initial trials with UK water companies. This partnership strengthens both companies positions in innovative environmental and healthcare monitoring solutions, with Aptamers technology playing a key role in enhancing public health through water purity protection.
APTA 06:01
Aptamer Group PLC
Notification of dealings by a director/PDMR
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the <mark style="background-color:yellow">purchase</mark> of ordinary shares by directors and other PDMRs in the Company.
APTA 06:01
Aptamer Group PLC
Therapeutic development agreement with Invizius
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc has signed a therapeutic development agreement with Invizius, a clinical-stage biotechnology company, to develop Optimer® binders targeting the complement system for treating inflammatory, fibrotic, and autoimmune diseases. The partnership aims to enhance Invizius H-Guard® therapy, making it safer and more precise by leveraging Aptamers synthetic oligonucleotide-based binders. These Optimers offer advantages such as enhanced specificity, biological stability, and reduced immunogenicity compared to protein-based therapeutics. The collaboration focuses on addressing diseases like IgA nephropathy, with the potential to tap into the $7.1 billion global market for complement-targeting therapies. Aptamer retains intellectual property rights for the developed binders, supporting future licensing and commercialization opportunities. The agreement aligns with Aptamers licensing-led growth model and reinforces its commitment to generating long-term shareholder value through royalty and licensing income. Invizius selected Aptamer for its expertise in delivering high-performance binders, highlighting the strategic fit and potential of aptamers as a future therapeutic modality.
APTA 06:01
Aptamer Group PLC
Block Listing Interim Review
APTA 06:01
Aptamer Group PLC
Biomarker Discovery Service Launch
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc (AIMAPTA) has launched a new **Biomarker Discovery Service**, leveraging its proprietary **Optimer® technology** and advanced proteomic analysis to rapidly identify and validate drug-development-ready biomarkers. This service targets the **US$62.4 billion global biomarker discovery market**, offering a fee-for-service model that accelerates biomarker identification from years to months. The platform simultaneously generates high-affinity binding molecules, enabling faster development of targeted therapies, diagnostics, and treatments.
The service addresses the critical need for biomarkers in precision medicine, particularly in areas with high unmet medical need. Early interest has been demonstrated, including successful internal application for Aptamer’s fibrotic liver delivery system. The launch supports Aptamer’s revenue diversification strategy, with minimal upfront investment and expected revenue enhancement in the current financial year.
CEO Dr. Arron Tolley highlighted the service’s potential to accelerate drug and diagnostic development, with two additional biomarker projects already underway. Aptamer’s Optimer® platform continues to expand its commercial impact, positioning the company as a leader in next-generation synthetic binders for the life sciences industry.
**Key Points**
Launch of Biomarker Discovery Service using Optimer® technology.
Targets US$62.4 billion global market with fee-for-service model.
Accelerates biomarker discovery from years to months.
Dual-output capabilityvalidated biomarkers + binding molecules.
Early interest and successful internal application demonstrated.
Expected revenue enhancement in the current financial year.
Supports Aptamer’s revenue diversification and growth strategy.
APTA 06:01
Aptamer Group PLC
Update on licensing and development progress
APTA 06:01
Aptamer Group PLC
Exercise of warrants
APTA 14:45
Aptamer Group PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
APTA 06:01
Aptamer Group PLC
Contract extension with global pharma partner

AI Crunch

Single-Ticker AI Crunch
APTA signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Aptamer Group PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full APTA AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for APTA on 2025-09-11.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
20126800
Enterprise Value
43277928
Public Float
66.72
Broker Target
180
Shares Out
3157145044
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BNRRP542
Market
None
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-09
Net Debt
-568000.0
Cash
1059000.0
EPS
-
Net Income
-2424000.0
Revenue
1203000.0
Enterprise Value
43277928
Trailing PE
-
Forward PE
-
Price Sales TTM
14.6058
Price Book MRQ
8.4078
EV Revenue
12.8794
EV EBITDA
-5.0596

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
26.5526
Institutions As Of
2025-08-07
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
0
Purchase TR1
4
Sale TR1
2
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit APTA.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-11 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Aptamer Group PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
APTA Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-11 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -14.55%
RSI Gauge
Price Change
AI Forecast